Category Universities vs Industry

On Average 3.5 patents per drug in 2005! and How private-sector follow-on patents affect socially responsible licensing efforts.


March-in rights on Federally funded research have not been effective at securing access to medicines. Non-exclusive licensing should be pursued instead.

Recent example of catastrophic licensing of university-invented drug

India slams U.S. on University partnerships with industry

US public research (NIH) translates into higher health impact than private research

Cochrane Collab founder Iain Chalmers challenges ABPI’s claim that 90% drugs come from industry

Half of all health R&D funding is from public/not-for-profit sources (2005, data from OECD + others)